The combination of amivantamab plus lazertinib in <i>EGFR</i> mutant NSCLC, and lorlatinib in <i>ALK</i> rearranged NSCLC, has improved efficacy outcomes as never before. The gene discussed is ALK; the disease is non-small cell lung carcinoma.